TY - JOUR T1 - Diagnostic performances of serum liver enzymes and cytokines in non-alcoholic fatty liver disease TT - Serum karaciğer enzimleri ve sitokinlerin alkolik olmayan yağlı karaciğer hastalığında tanısal performansları AU - Turkon, Hakan AU - Colak, Ayfer AU - Toprak, Burak AU - Yıldız, Coşkun AU - Hasturk, Aybike AU - Yıldız, Omur AU - Binnetoglu, Emine AU - Yener, Özlem PY - 2015 DA - May DO - 10.5799/ahinjs.01.2015.01.0479 JF - Journal of Clinical and Experimental Investigations JO - J Clin Exp Invest PB - Aydın ECE WT - DergiPark SN - 1309-8578 SP - 16 EP - 20 VL - 6 IS - 1 LA - en AB - Objective: Non-alcoholic fatty liver disease (NAFLD) is affecting people worldwide with increasing prevalence. Non-invasive tests are required for both diagnosis and staging of the disease. We aimed to evaluate diagnostic accuracy of routine liver enzymes and cytokines in NAFLD. Methods: A total of 88 cases, aged between 20 and 62 years, were included in the study. Serum ALT, AST, GGT, triglyceride, TNF-alpha, IL-6 and IL-8 were measured in 40 patients with NAFLD and in 48 healthy control patients with similar BMI and demographic characteristics. Diagnostic performances of serum biomarkers for diagnosis of NAFLD were evaluated with ROC analysis. Results: ALT and AST showed good diagnostic performance in predicting patients with NAFLD in the overall group (AUC=0.817; 95% CI[0.721-0.913], AUC=0.815; 95% CI[0.718-0.911] respectively) but in obese subjects ALT and AST showed poor performance (AUC=0.659; 95% CI[0.478-0.841], AUC=0.680; 95% CI[0.498-0.861] respectively). Among cytokines TNF-alpha showed best performance in the diagnosis of NAFLD in both overall group and obese subjects (AUC=0.892; 95% CI[0.824- 0.959], AUC=0.858; 95% CI[0.739-0.977] respectively). The optimal cut off value for TNF-alpha was 10.65pg/ml with a sensitivity of 75% and a specificity of 93% in the overall group. IL-6 and IL-8 showed poor performance. Conclusion: TNF-alpha may be a good parameter for predicting patients with NAFLD. J Clin Exp Invest 2015; 6 (1): 16-20 Key words: TNF-alpha, IL-8, IL 6, non-alcoholic fatty liver disease KW - TNF-alpha KW - IL-8 KW - IL 6 KW - non-alcoholic fatty liver disease N2 - Amaç: Alkolik olmayan yağlı karaciğer hastalığı gittikçe artan prevalansla dünya çapında insanları etkilemektedir. Bu hastalığın tanısı ve evrelendirilmesi için invaziv olmayan testlere ihtiyaç vardır. Bu çalışmada rutin karaciğer enzimleri ve sitokinlerin alkolik olmayan yağlı karaciğer hastalığında tanısal performanslarını değerlendirmeyi amaçladık.Yöntemler: 20-62 yaşları arasında 88 kişi çalışmaya dahil edildi. Serum ALT, AST, GGT, trigliserid, TNF-alfa, IL-6 ve IL-8 düzeyleri 40 yağlı karaciğer hastası ve benzer VKİ ve demografik özellikleri olan 48 sağlıklı bireyde ölçüldü. Serum biyobelirteçlerinin yağlı karaciğer hastalığındaki tanısal performansları ROC analizi ile değerlendirildi.Bulgular: ALT ve AST tüm grupta yağlı karaciğer hastalığı olan bireyleri belirlemede iyi performans gösterdi (AUC=0,817; %95 CI[0,721-0,913], AUC=0,815; %95 CI[0,718-0,911] sırasıyla) ancak obez bireylerde ALT ve AST zayıf performans gösterdi (AUC=0,659; %95 CI[0,478-0,841], AUC=0,680; %95 CI[0,498-0,861] sırasıyla). Sitokinler arasında TNF-alfa yağlı karaciğer hastalığı tanısında tüm grupta ve obez hastalarda en iyi performansı gösterdi (AUC=0,892; %95 CI[0,824-0,959], AUC=0,858; %95 CI[0,739-0,977] sırasıyla). Tüm grupta TNF-alfa için en iyi cut-off değeri %75 sensitivite ve %93 spesifisite ile 10,65pg/mL bulundu. IL6 ve IL8 zayıf performans gösterdi.Sonuç: TNF-alfa alkolik olmayan yağlı karaciğer hastalarını tespit etmede iyi bir parametre olabilir CR - Hjelkrem M.C, Torres D.M, Harrison S.A. Nonalcoholic CR - fatty liver disease. Minerva Med 2008;99:583-593. CR - Jarrar M.H, Baranova A, Collantes R, et al. Adipokines CR - and cytokines in non-alcoholic fatty liver disease. Aliment CR - Pharmacol Ther 2008;27:412-421. CR - Bjornsson E. The clinical aspects of non-alcoholic fatty liver CR - disease. Minerva Gastroenterol Dietol 2008;54:7-18. CR - Wang J.K, Feng Z.W, Li Y.C, et al. Association of tumor CR - necrosis factor-alpha gene promoter polymorphism at CR - sites -308 and -238 with non-alcoholic fatty liver disease: CR - a meta-analysis. J Gastroenterol Hepatol 2012;27:670- CR - Goren B and Fen T. Non-alkolik yağlı karaciğer hastalığı. CR - Türkiye Klinikleri J Med Sci 2005;25:841-850. CR - Tilg H. The role of cytokines in non-alcoholic fatty liver CR - disease. Dig Dis 2010;28:179-185. CR - Marchesini G, Brizi M, Morselli L.A.M, et al. Association CR - of nonalcoholic fatty liver disease with insulin resistance. CR - Am J Med 1999;107:450-455. CR - Schreuder T.C, Verwer B.J, van Nieuwkerk C.M, Mulder CR - CJ. Nonalcoholic fatty liver disease: an overview of current CR - insights in pathogenesis, diagnosis and treatment. CR - World J Gastroenterol 2008;14:2474-2486. CR - Pearce S.G, Thosani N.C, Pan J.J. Noninvasive biomarkers CR - for the diagnosis of steatohepatitis and advanced CR - fibrosis in NAFLD. Biomark Res 2013;1:7. CR - Kunde S.S, Lazenby A.J, Clements R.H, Abrams GA. CR - Spectrum of NAFLD and diagnostic implications of the CR - proposed new normal range for serum ALT in obese CR - women. Hepatology 2005;42:650-656. CR - Yamada C, Mitsuhashi T, Hiratsuka N, et al. Optimal reference CR - interval for homeostasis model assessment of CR - insulin resistance in a Japanese population. J Diabetes CR - Invest 2011;2:373-376. CR - Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and CR - risk factors for nonalcoholic fatty liver disease: the Dionysos CR - nutrition and liver study. Hepatology 2005;42:44- CR - Mofrad P, Contos M.J, Haque M, et al. Clinical and histologic CR - spectrum of nonalcoholic fatty liver disease associated CR - with normal ALT values. Hepatology 2003;37:1286- CR - Fracanzani A.L, Valenti L, Bugianesi E, et al. Risk of CR - severe liver disease in nonalcoholic fatty liver disease CR - with normal aminotransferase levels: a role for insulin CR - resistance and diabetes. Hepatology 2008;48:792-798. CR - Zelber S.S, Lotan R, Shlomai A, et al. Predictors for incidence CR - and remission of NAFLD in the general population CR - during a seven-year prospective follow-up. J Hepatol CR - ;56:1145-1151. CR - Caballeria L, Arteaga I, Pera G, et al. [Risk factors associated CR - with non-alcoholic fatty liver disease: a casecontrol CR - study]. Med Clin (Barc) 2013;141:233-239. CR - Abiru S, Migita K, Maeda Y, et al. Serum cytokine and CR - soluble cytokine receptor levels in patients with non-alcoholic CR - steatohepatitis. Liver Int 2006;26:39-45. CR - Hui JM, Hodge A, Farrell G.C, et al. Beyond insulin resistance CR - in NASH: TNF-alpha or adiponectin? Hepatology CR - ;40:46-54. CR - Lebensztejn DM, Kowalczuk D, Tarasow E, et al. Tumor CR - necrosis factor alpha and its soluble receptors in obese CR - children with NAFLD. Adv Med Sci 2010;55:74-79. CR - Manco M, Marcellini M, Giannone G, Nobili V. Correlation CR - of serum TNF-alpha levels and histologic liver injury CR - scores in pediatric nonalcoholic fatty liver disease. Am J CR - Clin Pathol 2007;127:954-960. UR - https://doi.org/10.5799/ahinjs.01.2015.01.0479 L1 - https://dergipark.org.tr/en/download/article-file/104471 ER -